Waters Corp's India business boosted by rush for weight-loss drugs

Kashish Tandon

Thu, May 15, 2025, 4:48 AM 2 min read

By Kashish Tandon

BENGALURU (Reuters) -U.S.-based Waters Corp, which makes aesculapian instrumentality utilized successful objective testing, has seen a spurt successful request from drugmakers successful India rushing to make their versions of fashionable weight-loss drugs, a elder enforcement told Reuters.

Semaglutide, the progressive constituent successful Novo Nordisk's Wegovy and diabetes medicine Ozempic, goes disconnected patent successful India successful 2026, paving the mode for cheaper versions of the drugs.

Local drugmakers including Biocon, Cipla, Dr. Reddy's and Lupin person been racing to marque generic versions of these drugs to drawback a stock of the planetary marketplace estimated to beryllium worthy $150 cardinal successful the adjacent decade.

"India volition beryllium the starring subordinate successful GLP drugs arsenic good due to the fact that we are successful generics and we person manufacturing facilities to support," said T. Anil Kumar, vice president of Water's India business, referring to the people of weight-loss drugs known arsenic GLP-1 agonists.

Waters, based successful Milford, Massachusetts, makes laboratory equipment, bundle and different tools utilized successful objective investigating by drugmakers and biotech companies. Its India portion contributes astir 8% to Waters' sales.

"A batch of enactment is coming to India... truthful I spot this arsenic an accidental for us," Kumar said.

Waters is expecting gross maturation percent successful the treble digits successful India connected the backmost of these maturation drivers, helium added.

Waters Corp operates 9 sites successful India with implicit 430 employees. The institution is headquartered successful the tech hub of Bengaluru, wherever it besides opened a Global Capability Center successful 2023.

The institution expects yearly maturation publication of 70-100 ground points from its India concern successful the near-term and a 30 ground points boost from investigating for GLP-1 drugs.

Last week, the institution raised its yearly nett forecast and reported better-than-expected quarterly results connected higher request successful Asia and the Americas.

(Reporting by Kashish Tandon successful Bengaluru; Editing by Krishna Chandra Eluri)